Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update
María Reig, Alejandro Forner, Jordi Rimola, et al.
Journal of Hepatology (2021) Vol. 76, Iss. 3, pp. 681-693
Open Access | Times Cited: 2794

Showing 26-50 of 2794 citing articles:

New concepts in the treatment of hepatocellular carcinoma
Sabrina Sidali, Eric Trépo, Olivier Sutter, et al.
United European Gastroenterology Journal (2022) Vol. 10, Iss. 7, pp. 765-774
Open Access | Times Cited: 74
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study
Claudia Angela Maria Fulgenzi, Jaekyung Cheon, Antonio D’Alessio, et al.
European Journal of Cancer (2022) Vol. 175, pp. 204-213
Open Access | Times Cited: 74
Achievement of Complete Response and Drug-Free Status by Atezolizumab plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-Stage Hepatocellular Carcinoma: A Multicenter Proof-Of-Concept Study
Masatoshi Kudo, Tomoko Aoki, Kazuomi Ueshima, et al.
Liver Cancer (2023) Vol. 12, Iss. 4, pp. 321-338
Open Access | Times Cited: 68
Immune checkpoint inhibitors in hepatocellular carcinoma: emerging challenges in clinical practice
Matthias Pinter, Bernhard Scheiner, David J. Pinato
˜The œLancet. Gastroenterology & hepatology (2023) Vol. 8, Iss. 8, pp. 760-770
Closed Access | Times Cited: 57
Imaging to Predict Prognosis in Hepatocellular Carcinoma: Current and Future Perspectives
Maxime Ronot, Victoria Chernyak, Adam M. Burgoyne, et al.
Radiology (2023) Vol. 307, Iss. 3
Closed Access | Times Cited: 54
Camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and hepatic artery infusion chemotherapy for hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (TRIPLET): a phase II study
Tianqi Zhang, Zhijun Geng, Mengxuan Zuo, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 53
Nonalcoholic fatty liver disease and hepatocellular carcinoma:Insights in epidemiology, pathogenesis, imaging, prevention and therapy
Stergios A. Pοlyzos, Lampros Chrysavgis, Ilias D. Vachliotis, et al.
Seminars in Cancer Biology (2023) Vol. 93, pp. 20-35
Closed Access | Times Cited: 48
Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study
Zhi‐Cheng Jin, Jian-Jia Chen, Xiaoli Zhu, et al.
EClinicalMedicine (2024) Vol. 72, pp. 102622-102622
Open Access | Times Cited: 48
Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab–bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study
Qinghe Zeng, Christophe Klein, Stefano Caruso, et al.
The Lancet Oncology (2023) Vol. 24, Iss. 12, pp. 1411-1422
Open Access | Times Cited: 47
Cisplatin in Liver Cancer Therapy
Sae Hamaya, Kyoko Oura, Asahiro Morishita, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 13, pp. 10858-10858
Open Access | Times Cited: 43
Biomarkers for diagnosis and therapeutic options in hepatocellular carcinoma
Yau-Tuen Chan, Cheng Zhang, Junyu Wu, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 38
MASLD and the Development of HCC: Pathogenesis and Therapeutic Challenges
Anju Phoolchund, Salim I. Khakoo
Cancers (2024) Vol. 16, Iss. 2, pp. 259-259
Open Access | Times Cited: 32
EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma
Bruno Sangro, Lorenza Rimassa, Maxime Ronot, et al.
Journal of Hepatology (2024)
Closed Access | Times Cited: 30
Merits and boundaries of the BCLC staging and treatment algorithm: Learning from the past to improve the future with a novel proposal
Franco Trevisani, Alessandro Vitale, Masatoshi Kudo, et al.
Journal of Hepatology (2024) Vol. 80, Iss. 4, pp. 661-669
Closed Access | Times Cited: 25
Portal Venous and Hepatic Arterial Coefficients Predict Post-Hepatectomy Overall and Recurrence-Free Survival in Patients with Hepatocellular Carcinoma: A Retrospective Study
Yu-Kai Li, Song Wu, Yu-Shan Wu, et al.
Journal of Hepatocellular Carcinoma (2024) Vol. Volume 11, pp. 1389-1402
Open Access | Times Cited: 25
Navigating the landscape of liver cancer management: Study designs in clinical trials and clinical practice
Giuseppe Cabibbo, Ciro Celsa, Lorenza Rimassa, et al.
Journal of Hepatology (2024) Vol. 80, Iss. 6, pp. 957-966
Open Access | Times Cited: 21
HCC-Related lncRNAs: Roles and Mechanisms
Mimansha Shah, Devanand Sarkar
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 1, pp. 597-597
Open Access | Times Cited: 19
Improved Clinical Staging System for Localized Pancreatic Cancer Using the ABC Factors: A TAPS Consortium Study
E. Dekker, Jacob L. van Dam, Quisette P. Janssen, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 12, pp. 1357-1367
Closed Access | Times Cited: 19
Rhein‐based Pickering emulsion for hepatocellular carcinoma: Shaping the metabolic signaling and immunoactivation in transarterial chemoembolization
Xiaoliu Liang, Hui Liu, Hu Chen, et al.
Aggregate (2024) Vol. 5, Iss. 4
Open Access | Times Cited: 19
Antiviral Therapy Utilization and 10-Year Outcomes in Resected Hepatitis B Virus– and Hepatitis C Virus–Related Hepatocellular Carcinoma
Daniel Q. Huang, Joseph Hoang, Rubayet Kamal, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 7, pp. 790-799
Closed Access | Times Cited: 18
Recent Progress in Systemic Therapy for Advanced Hepatocellular Carcinoma
Narayanan Sadagopan, Aiwu Ruth He
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 2, pp. 1259-1259
Open Access | Times Cited: 18
British Society of Gastroenterology guidelines for the management of hepatocellular carcinoma in adults
Abid Suddle, Helen L. Reeves, Richard Hubner, et al.
Gut (2024) Vol. 73, Iss. 8, pp. 1235-1268
Open Access | Times Cited: 18
Hepatocellular carcinoma
Alexandra M. Adams, Ahmed O. Kaseb, Hop S. Tran Cao
Elsevier eBooks (2024), pp. 27-39
Closed Access | Times Cited: 17
Emerging role of molecular diagnosis and personalized therapy for hepatocellular carcinoma
Ming-Da Wang, Yong‐Kang Diao, Lan‐Qing Yao, et al.
iLiver (2024) Vol. 3, Iss. 1, pp. 100083-100083
Open Access | Times Cited: 16
The future of liver transplantation
Sandy Feng, Garrett R. Roll, Foad J. Rouhani, et al.
Hepatology (2024)
Closed Access | Times Cited: 16

Scroll to top